Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939382 | 0.88 | ALOX5AP (0.36) | DUTALOX5APFEN1PTGES2 | |
| SCHEMBL1939237 | 0.85 | ALDH1A1 (0.40) | KDM4EALDH1A1L3MBTL1DUTALOX5AP | |
| SCHEMBL1940129 | 0.83 | KDM4E (0.37) | KDM4EALDH1A1L3MBTL1DUTALOX5AP | |
| SCHEMBL1939366 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1L3MBTL1DUTLMNA | |
| SCHEMBL1169142 | 0.76 | PSEN1 (0.50) | KDM4EALDH1A1L3MBTL1PTGES2TSHR | |
| SCHEMBL1938338 | 0.74 | ALDH1A1 (0.40) | ALDH1A1PTGES2TSHRSMN1; SMN2 | |
| SCHEMBL1938183 | 0.73 | ADORA3 (0.41) | KDM4EALDH1A1L3MBTL1ALOX5APFEN1 | |
| SCHEMBL1349064 | 0.73 | ALDH1A1 (0.37) | KDM4EALDH1A1L3MBTL1ALOX5APFEN1 | |
| SCHEMBL1939267 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1ALOX5APFEN1 | |
| SCHEMBL1938603 | 0.73 | PSEN1 (0.38) | PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851225-B1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | claimed |
| JP-2008530042-A | — | — | 2008-08-07 | — | — | JP | claimed |
| US-7361659-B2 | Pyrrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | claimed |
| EP-1851225-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-07 | — | — | EP | claimed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | claimed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-1851225-B1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-7361659-B2 | Pyrrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | KDM4E 2684/4885ALDH1A1 617/4885L3MBTL1 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.